MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL.

about

MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL.

Item

http://www.wikidata.org/entity/Q47634902

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

MYC/BCL2 Co-Expression Is a St ...... fication in Primary CNS DLBCL.

@en

MYC/BCL2 Co-Expression Is a St ...... fication in Primary CNS DLBCL.

@nl

type

Item

label

MYC/BCL2 Co-Expression Is a St ...... fication in Primary CNS DLBCL.

@en

MYC/BCL2 Co-Expression Is a St ...... fication in Primary CNS DLBCL.

@nl

prefLabel

MYC/BCL2 Co-Expression Is a St ...... fication in Primary CNS DLBCL.

@en

MYC/BCL2 Co-Expression Is a St ...... fication in Primary CNS DLBCL.

@nl

P1476

MYC/BCL2 Co-Expression Is a St ...... fication in Primary CNS DLBCL.

@en

P2093

Jie Ma

http://www.w3.org/2001/XMLSchema#string

Jing-Huan Lv

http://www.w3.org/2001/XMLSchema#string

Qian-Yun Shi

http://www.w3.org/2001/XMLSchema#string

Qiu Rao

http://www.w3.org/2001/XMLSchema#string

Qun-Li Shi

http://www.w3.org/2001/XMLSchema#string

Wei Bao

http://www.w3.org/2001/XMLSchema#string

Xiao Feng

http://www.w3.org/2001/XMLSchema#string

Xuan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

RETRACTED: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)

Stromal gene signatures in large-B-cell lymphomas

MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.

MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.

P304

942-948

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNEN/NLX083

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29044419

http://www.w3.org/2001/XMLSchema#string